Altus Power Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $229.32 billion. The enterprise value is $254.44 billion.
| Market Cap | 229.32B |
| Enterprise Value | 254.44B |
Important Dates
The last earnings date was Tuesday, July 29, 2025, before market open.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Aug 8, 2025 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 27.65 and the forward PE ratio is 15.25.
| PE Ratio | 27.65 |
| Forward PE | 15.25 |
| PS Ratio | 4.06 |
| Forward PS | 7.39 |
| PB Ratio | 5.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 20.52 |
| P/OCF Ratio | 17.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.30, with an EV/FCF ratio of 22.77.
| EV / Earnings | 30.67 |
| EV / Sales | 4.50 |
| EV / EBITDA | 13.30 |
| EV / EBIT | 17.73 |
| EV / FCF | 22.77 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 0.74.
| Current Ratio | 0.86 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 2.95 |
| Interest Coverage | 10.77 |
Financial Efficiency
Return on equity (ROE) is 19.67% and return on invested capital (ROIC) is 11.88%.
| Return on Equity (ROE) | 19.67% |
| Return on Assets (ROA) | 8.28% |
| Return on Invested Capital (ROIC) | 11.88% |
| Return on Capital Employed (ROCE) | 18.19% |
| Revenue Per Employee | $608,192 |
| Profits Per Employee | $89,290 |
| Employee Count | 92,900 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, AstraZeneca has paid $1.72 billion in taxes.
| Income Tax | 1.72B |
| Effective Tax Rate | 17.17% |
Stock Price Statistics
The stock price has decreased by -8.83% in the last 52 weeks. The beta is 0.15, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -8.83% |
| 50-Day Moving Average | 71.63 |
| 200-Day Moving Average | 70.53 |
| Relative Strength Index (RSI) | 58.09 |
| Average Volume (20 Days) | 5,446,962 |
Short Selling Information
The latest short interest is 6.25 million, so 0.20% of the outstanding shares have been sold short.
| Short Interest | 6.25M |
| Short Previous Month | 6.81M |
| Short % of Shares Out | 0.20% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.53 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $56.50 billion and earned $8.30 billion in profits. Earnings per share was $5.31.
| Revenue | 56.50B |
| Gross Profit | 46.48B |
| Operating Income | 14.35B |
| Pretax Income | n/a |
| Net Income | 8.30B |
| EBITDA | 19.13B |
| EBIT | 14.35B |
| Earnings Per Share (EPS) | $5.31 |
Balance Sheet
The company has $7.11 billion in cash and $32.94 billion in debt, giving a net cash position of -$25.83 billion or -$16.67 per share.
| Cash & Cash Equivalents | 7.11B |
| Total Debt | 32.94B |
| Net Cash | -25.83B |
| Net Cash Per Share | -$16.67 |
| Equity (Book Value) | 44.81B |
| Book Value Per Share | 28.85 |
| Working Capital | -4.60B |
Cash Flow
In the last 12 months, operating cash flow was $13.39 billion and capital expenditures -$2.21 billion, giving a free cash flow of $11.18 billion.
| Operating Cash Flow | 13.39B |
| Capital Expenditures | -2.21B |
| Free Cash Flow | 11.18B |
| FCF Per Share | $7.21 |
Margins
Gross margin is 82.26%, with operating and profit margins of 25.40% and 14.68%.
| Gross Margin | 82.26% |
| Operating Margin | 25.40% |
| Pretax Margin | 17.74% |
| Profit Margin | 14.68% |
| EBITDA Margin | 33.85% |
| EBIT Margin | 25.40% |
| FCF Margin | 19.78% |
Dividends & Yields
This stock pays an annual dividend of $1.54, which amounts to a dividend yield of 2.06%.
| Dividend Per Share | $1.54 |
| Dividend Yield | 2.06% |
| Dividend Growth (YoY) | 5.50% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 28.92% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 1.99% |
| Earnings Yield | 3.62% |
| FCF Yield | 4.87% |
Analyst Forecast
The average price target for AstraZeneca is $95.00, which is 27.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $95.00 |
| Price Target Difference | 27.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 6.57% |
| EPS Growth Forecast (5Y) | 9.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 27, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2015 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 6 |